Clinical Trial Update: Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating ferumoxytol- and gadolinium-labeled MRI to measure brain tumors before or after treatment has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Brain Neoplasm
• Brain Tumor

Drugs mentioned

• ferumoxytol- and gadolinium-labeled MRI

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2023-09-07